D
David R. Sullivan
Researcher at Royal Prince Alfred Hospital
Publications - 239
Citations - 20489
David R. Sullivan is an academic researcher from Royal Prince Alfred Hospital. The author has contributed to research in topics: Cholesterol & Diabetes mellitus. The author has an hindex of 59, co-authored 222 publications receiving 18915 citations. Previous affiliations of David R. Sullivan include University of Sydney & Alfred Hospital.
Papers
More filters
Journal ArticleDOI
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
Andrew Tonkin,P. Alyward,David Colquhoun,Paul Glasziou,P. Harris,D. Hunt,Anthony C Keech,Stephen MacMahon,P. Magnus,D. Newel,P. Nestel,N. Sharpe,J. Shaw,R. J. Simes,P. Thompson,Alexis A. Thompson,Malcolm J. West,H. White,S. Simes,Wendy Hague,Sue Caleo,Jane Hall,Andrew J. Martin,S. Mulray,Philip J. Barter,Lawrence J. Beilin,Rory Collins,John J McNeil,Petra Meier,H. Willimott,D. Smithers,P. Wallace,J. Baker,M. Hobbs,David R. Sullivan,N. Anderson,Graeme J. Hankey,John D.G. Watson,M. Arulchelvam,S. Chup,John Daly,J. Hanna,A. Leach,M. Lee,J. Loughhead,H. Lundie-Jenkin,J. Morrison,S. Netting,A. Nguyen,H. Pater,R. Philip,G. Pinna,D. Rattos,S. Ryerson,V. Sazhin,Richard Walsh,A. Claque,M. Mackie,Julie Jane Yallop,K. Boss,M. Shepard,J. Leach,M. Gandy,J. Joughin,J. Seabrook,R. Abraham,J. Allen,F. Bates,I. Beinart,E. Breed,D. Brown,N. Bunyan,D. Calvert,T. Campbell,D. Condon-Paoloni,B. Conway,Lucy A. Coupland,J. Crowe,N. Cunio,B. Cuthbert,N. Cuthbert,S. D'Arcy,Patricia M. Davidson,B. Dwyer,J. England,C. Friend,Greg Fulcher,S. Grant,K. Hellestrand,M. Kava,Leonard Kritharides,D. McGill,H. McKee,Allan J. McLean,M. Neaverson,G. Nelson,M. O'Neill,C. Onuma,F. O'Reilly +98 more
TL;DR: Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.
Journal ArticleDOI
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Anthony C Keech,R. J. Simes,Philip J. Barter,James D. Best,Russell S. Scott,Marja-Riitta Taskinen,Peta M. Forder,Avinesh Pillai,Tamara M. Davis,Paul Glasziou,Paul L. Drury,Y A Kesäniemi,David R. Sullivan,D Hunt,Peter G. Colman,Michael C d'Emden,Malcolm J. Whiting,Christian Ehnholm,Markku Laakso +18 more
TL;DR: Fenofibrate did not significantly reduce the risk of the primary outcome of coronary events, but it did reduce total cardiovascular events, mainly due to fewer non-fatal myocardial infarctions and revascularisations.
Journal ArticleDOI
Health benefits of herbs and spices: the past, the present, the future
Linda C Tapsell,Ian Hemphill,Lynne Cobiac,Craig S Patch,David R. Sullivan,Michael Fenech,Steven Roodenrys,Jennifer B Keogh,Peter M. Clifton,Peter M. Clifton,Peter Williams,Virginia A Fazio,Karen E Inge +12 more
TL;DR: The role of herbs and spices in health benefits is discussed in this paper, where the authors consider the use of herbs as a source of antioxidants to combat oxidation in a healthy diet.
Journal ArticleDOI
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2) : a randomised, double-blind, placebo-controlled trial
Frederick J. Raal,Evan A. Stein,Robert Dufour,Traci Turner,Fernando Civeira,Lesley J. Burgess,Gisle Langslet,Russell S. Scott,Anders G. Olsson,David R. Sullivan,G. Kees Hovingh,Bertrand Cariou,Ioanna Gouni-Berthold,Ransi Somaratne,Ian Bridges,Rob Scott,Scott M. Wasserman,Daniel Gaudet +17 more
TL;DR: In patients with heterozygous familial hypercholesterolaemia, evolocumab administered either 140 mg every 2 weeks or 420 mg monthly was well tolerated and yielded similar and rapid 60% reductions in LDL cholesterol compared with placebo.
Journal ArticleDOI
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance : The GAUSS-2 Randomized, Placebo-Controlled Phase 3 Clinical Trial of Evolocumab
Erik S.G. Stroes,David Colquhoun,David R. Sullivan,Fernando Civeira,Robert S. Rosenson,Gerald F. Watts,Eric Bruckert,Leslie Cho,Ricardo Dent,Beat Knusel,Allen Xue,Rob Scott,Scott M. Wasserman,Michael Rocco +13 more
TL;DR: Robust efficacy combined with favorable tolerability makes evolocumab a promising therapy for addressing the largely unmet clinical need in high-risk patients with elevated cholesterol who are statin intolerant.